Impax Laboratories IPXL
-
Impax Laboratories Management Discusses Q1 2013 Results - Earnings Call Transcript
Impax Laboratories ( IPXL ) Q1 2013 Earnings Call May 01, 2013 4:30 pm ET Executives ..... href='http://seekingalpha.com/article/1392231- impax - laboratories -management-discusses-q1-2013-results-earnings-call …
-
Impax Labs ( IPXL ): Q1 EPS of $0.37 beats by $0.16. Revenue of $148.5M beats by $19.65M. (PR)
Impax Labs ( IPXL ): Q1 EPS of $0.37 beats by $0.16 . Revenue of $148.5M beats by $19.65M . ( PR ) Post your comment!
-
Notable earnings after Wednesday’ s close: [[ALL]], [[ARI]], [[ARR]], [[ATML]], [[ATO]], [[ATW]], [[AXLL]], [[AXTI]], [[BKD]], [[BMR]], [[CACI]], [[CAR]], [[CBS]], [[CJES]], [[CNQR]], [[CSOD]], ...
… CWT , CXO , DVR , DX , DXCM , DXPE , EDMC , ESS , EXPD , EXXI , FB , FNF , FRT , G , GLUU , GNK , GTAT , HNSN , HR , IPI , IPXL , IVR , JDSU , KIM , LNC , LOCK , LVS , MAC , MAR , MET , MUR , NAVB , NGD , NLY , NTRI , PHH , POL , PRU , PSE , PXD , QUIK …
-
GlaxoSmithKline ([[GSK]] +0.1%) breaks off its relationship with Impax Laboratories ([[ IPXL ]] -1.1%) regarding the experimental Parkinson's drug Rytary due to "delays in the anticipated regulatory ...
… GSK +0.1% ) breaks off its relationship with Impax Laboratories ( IPXL -1.1% ) regarding the experimental Parkinson ..... market Rytary outside of the U.S. and Taiwan. IPXL shares have yet to fully recover from a steep decline …
-
Impax, GSK end Parkinson's disease partnership
April 29 (Reuters) - Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug.
-
FDA Bars Old OxyContin Generics: Read-Through To Continue Boosting Endo
By PropThink : By Jake King On Tuesday, the FDA ruled that generic drugmakers are barred from selling copies of older, easily abused formulations of Purdue Pharma's well-known pain killer OxyContin, which it originally reformulated to include abuse-deterrent qualities in 2010. Endo Pharmaceuticals
-
Curing Parkinson's: The Alternative Approach - Is There Money To Be Made?
By Ed Liston : In this article, I will make a comparison between available treatment for Parkinson's disease, and a few new options that might soon be available in the market. While describing the potential market for these options, I will also show that, with some due diligence, these new options
-
Premarket gainers: [[HIMX]] +21%. [[ASNA]] +13%. [[ACRX]] +12%. [[MTG]] +11%. [[SNTS]] +9%. [[CREE]] +6%.Losers: [[ IPXL ]] -21%. [[RNIN]] -16%.
Premarket gainers: HIMX +21% . ASNA +13% . ACRX +12% . MTG +11% . SNTS +9% . CREE +6% . Losers: IPXL -21% . RNIN -16% . Post your comment!
-
Impax Laboratories ( IPXL ) gets hammered after FDA inspectors say they've found continuing problems at the company's Hayward, California manufacturing facility that may affect new and pending drug ...
Impax Laboratories ( IPXL ) gets hammered after FDA inspectors say they've found continuing problems at the company's Hayward, California manufacturing …
-
After-hours top gainers, as of 5:15 p.m.: [[ASNA]] +13%. [[SNTS]] +8%. [[CPWR]] +4%. [[NDZ]] +3%. [[MTG]] +3%. After-hours top losers: [[ IPXL ]] -20%. [[JCP]] -6%. [[GMXR]] -6%. [[TVL]] -3%. [[NSU]] ...
After-hours top gainers, as of 5:15 p.m.: ASNA +13% . SNTS +8% . CPWR +4% . NDZ +3% . MTG +3% . After-hours top losers: IPXL -20% . JCP -6% . GMXR -6% . TVL -3% . NSU -3% . Post your comment!